DataString Consulting Company Logo
DataString Consulting Company Logo
Glycopyrronium Tosylate Market
Home»Top Market Reports»Glycopyrronium Tosylate Market

Glycopyrronium Tosylate Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802248, Published - May 2025

Segmented in Dosage Form (Pre-moistened Topical Wipe, Cream), Application Areas (Hyperhidrosis Treatment, Bronchodilation Therapy, Reducing Salivary Secretions, Dermatologic Disorders, Others), End-Use, Distribution Channel and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Glycopyrronium Tosylate Market Outlook

The market, for Glycopyrronium tosylate was estimated at $400.9 million in 2024; and it is anticipated to increase to $894.0 million by 2030 with projections indicating a growth to around $1.7 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 14.3% over the forecast period. This significant growth trend symbolizes the importance of Glycopyrronium Tosylate in the field according to key players who see it as a popular remedy for different medical issues and a vital component of healthcare overall. The consistent focus on creating therapies for neurological and respiratory ailments in response to an aging worldwide population and growing health consciousness among people globally has been the primary catalyst, for this positive development. The increasing occurrence of long term health conditions and the need for treatment choices have significantly boosted the importance of Glycopyrronium Tosylate to unprecedented levels, in the worldwide pharmaceutical industry.


The medication Glycopyrronium Tosylate is considered an anticholinergic with qualities that make it essential in modern healthcare settings. Its role in alleviating bronchospasms linked to obstructive pulmonary disease (COPD) gastrointestinal disorders and its use, in treating excessive salivation and drooling is well established.


Market Size Forecast & Key Insights

2019
$400M2024
2029
$1.5B2034

Absolute Growth Opportunity = $1.1B

The Glycopyrronium Tosylate market is projected to grow from $400.9 million in 2024 to $1.53 billion in 2034. This represents a CAGR of 14.3%, reflecting rising demand across Hyperhidrosis Treatment, Reducing Salivary Secretions and Bronchodilation Therapy.

The Glycopyrronium Tosylate market is set to add $1.1 billion between 2024 and 2034, with manufacturer targeting Bronchodilation Therapy & Reducing Salivary Secretions Application Areas projected to gain a larger market share.

With Increasing demand for antiperspirants, and Pharmaceutical industry growth, Glycopyrronium Tosylate market to expand 281% between 2024 and 2034.

Opportunities in the Glycopyrronium Tosylate Market

Rapidly Growing Demand in Dermatology

There is a growing demand for Glycopyrronium Tosylate in dermatology for treating underarm sweating due to more people focusing on personal care and hygiene nowadays. This trend offers growth opportunities for Glycopyrronium Tosylate manufacturers, in an untapped market segment.

Technological Advances in Drug Delivery Systems and Expansion into Emerging Markets

The pharmaceutical sector is currently experiencing a wave of advancements focused on drug delivery mechanisms as a key area of development progressions in the industry. Glycopyrronium Tosylate. A component in specific medications. Stands to gain from these breakthroughs. Revolutionary delivery techniques such as patches or nano based formulations are poised to not only just enhance the effectiveness of the drug but also elevate the overall experience, for patients.

In countries like India and China that are still developing economically and have populations in need of medical care services will see a significant boost in demand if There is an increase, in the production or sales of Glycopyrronium Tosylate there. Collaborating strategically with pharmaceutical companies based locally and customizing strategies to meet the needs of these regions could drive further growth in the market.

Growth Opportunities in North America and Europe

Europe Outlook

Europe is seen as a market for Glycopyrronium Tosylate due to the increasing number of older individuals and the higher incidence of chronic conditions like Chronic Obstructive Pulmonary Disease highlighting the therapeutic benefits of Glycopyrronium Tosylate in these cases. The market growth in this region is also boosted by the support from agencies like the European Medicines Agency which promotes active research and development efforts related to Glycopyrronium Tosylate. Many known pharmaceutical companies such as Novartis and GlaxoSmithKline are based in this region and contribute to strong competition, in the industry.

North America Outlook

The market for Glycopyrronium Tosylate in North America is doing well due to the regions healthcare system and strong pharmaceutical industry presence. Enough the United States has embraced the use of Glycopyrronium Tosylate in its healthcare practices because it is effective, in managing Hyperhidrosis—a condition that causes excessive sweating and affects many Americans significantly. Moreover significant companies in the region like Pfizer and Merck are consistently investigating its uses; the introduction of generic versions of Glycopyrronium Tosylate also plays a significant role in driving up demand. However challenges arise for market entry and growth due to FDA rules and intense competition, in place.

North America Outlook

The market for Glycopyrronium Tosylate in North America is doing well due to the regions healthcare system and strong pharmaceutical industry presence. Enough the United States has embraced the use of Glycopyrronium Tosylate in its healthcare practices because it is effective, in managing Hyperhidrosis—a condition that causes excessive sweating and affects many Americans significantly. Moreover significant companies in the region like Pfizer and Merck are consistently investigating its uses; the introduction of generic versions of Glycopyrronium Tosylate also plays a significant role in driving up demand. However challenges arise for market entry and growth due to FDA rules and intense competition, in place.

Europe Outlook

Europe is seen as a market for Glycopyrronium Tosylate due to the increasing number of older individuals and the higher incidence of chronic conditions like Chronic Obstructive Pulmonary Disease highlighting the therapeutic benefits of Glycopyrronium Tosylate in these cases. The market growth in this region is also boosted by the support from agencies like the European Medicines Agency which promotes active research and development efforts related to Glycopyrronium Tosylate. Many known pharmaceutical companies such as Novartis and GlaxoSmithKline are based in this region and contribute to strong competition, in the industry.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Canada, UK, Germany, Australia are expected to grow at 12.9% to 17.2% CAGR

2

Emerging Markets : Brazil, South Africa, Indonesia are expected to grow at 10.0% to 15.0% CAGR

Market Analysis Chart

The market for Glycopyrronium Tosylate is being propelled by several drivers that are impacting its current trajectory and hold great potential for its future growth. Among the key catalysts sparking momentum in the market is the increasing prevalence of diseases such as hyperhidrosis and chronic bronchitis that require Glycopyrronium Tosylate as a treatment option, signalling a positive growth curve for this medication.

Recent Developments and Technological Advancement

October 2024

PharmaGen Inc announced their success in formulating a potent Glycopyrronium Tosylate solution with enhanced bioavailability

September 2024

BioSpectra introduced advanced separation technologies to increase the purity of Glycopyrronium Tosylate

July 2024

Revive Therapeutics secured FDA approval for its newest Glycopyrronium Tosylate-based product, aimed at controlling excessive sweating.

Glycopyrronium Tosylate, a medication significant in the healthcare industry, has exhibited some remarkable progress in recent market developments. This active pharmaceutical ingredient, earning its recognition primarily as an anticholinergic agent, plays a crucial role in treating hyperhidrosis conditions.

Impact of Industry Transitions on the Glycopyrronium Tosylate Market

As a core segment of the Pharmaceutical industry, the Glycopyrronium Tosylate market develops in line with broader industry shifts. Over recent years, transitions such as Growing Emphasis on Therapeutic Design and Advancement in Drug Delivery System Technology have redefined priorities across the Pharmaceutical sector, influencing how the Glycopyrronium Tosylate market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Growing Emphasis on Therapeutic Design:

The pharmaceutical industry is experiencing a shift towards innovative therapeutic approaches lately which has had a significant influence on how complex molecules like Glycopyrronium Tosylate are developed and used in treatments. This shift is primarily driven by the emergence of targeted medications that are tailored to interact with biological pathways redefining the way diseases are treated in the field. Glycopyrronium Tosylate is widely known for its effectiveness and precision in addressing conditions such as hyperhidrosis and COPD serving as an example of this evolving approach, to therapeutic design. The molecules widespread use in the market demonstrates that the industry, as a whole acknowledges the importance of targeting treatments with precision.

2

Advancement in Drug Delivery System Technology:

Parallel to this, there is an accelerating transition in the realm of drug delivery systems. Previously, the traditional mode of systemic drug delivery predominated, but the industry has swiftly embraced more effective and patientfriendly modes of administration. The usage of Glycopyrronium Tosylate in transdermal patches and inhalers illustrates this transition perfectly.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Glycopyrronium Tosylate market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Increasing Demand for Antiperspirants, and Technological Advancements in Drug Delivery Systems

The use of Glycopyrronium Tosylate in antiperspirants has also become increasingly important because of its ability to block sweat production effectively over periods of time as the demand for reliable and durable antiperspirants continues to increase in the market as well Its effectiveness, in helping to manage excessive sweating problems is also a significant application that is also driving the growth of its market.
The development of advanced drug delivery systems has also revolutionized treatment methodologies. Glycopyrronium Tosylates application in innovative therapeutic systems like transdermal patches and topical solutions has also boosted its significance in the industry.
The pharmaceutical sector is also seeing expansion with the emergence of new therapies gaining prominence in the realm of anticholinergic medications specifically targeting Glycopyrronium Tosylate—a commonly used anticholinergic drug that finds widespread use in managing conditions like excessive sweating and chronic obstructive pulmonary disease . Its varied medical uses underscore its contribution to advancements, in the pharmaceutical field and thereby driving up its market need.

Restraint: Regulatory Challenges

Similar to the pharmaceutical industry sector the market for Glycopyrronium Tosylate is subject to strict regulations as well. The process of approving drugs and treatments typically involves long approval timelines and significant uncertainty. Glycopyrronium Tosylate, a medication used to address conditions like hyperhidrosis must undergo thorough testing and regulatory steps before being cleared for consumer use. This obstacle may slow down the introduction of products into the market thus posing a challenge, to market growth.

Challenge: Competition from Alternatives

Besides regulatory challenges, Glycopyrronium Tosylate is also faced with stiff competition from similar drugs and alternative treatment options. Patients and healthcare providers may opt for other medications offering similar benefits but with possibly fewer side effects or a more affordable price point. This competitive landscape inevitably affects the market demand and dynamics of Glycopyrronium Tosylate, restraining its broader market penetration and growth.

Supply Chain Landscape

Raw Material Procurement

Sigma-Aldrich

Fisher Scientific

Chemical Synthesis

GSK

Novartis

Drug formulating
Dermira / G&W Laboratories
Distribution & Retailing
CVS Health / Walgreens. Ensure the content describes the **primary** and **secondary** applications of Glycopyrronium Tosylate. Use " / " to separate each application. No need to explain or describe each application. Stick to the specified format. Make sure the applications are relevant in the current market and industrial usage. Don't use words like "main uses" / "application1" or similar words
Raw Material Procurement

Sigma-Aldrich

Fisher Scientific

Chemical Synthesis

GSK

Novartis

Drug formulating

Dermira

G&W Laboratories

Distribution & Retailing

CVS Health

Walgreens. Ensure the content describes the **primary** and **secondary** applications of Glycopyrronium Tosylate. Use "

" to separate each application. No need to explain or describe each application. Stick to the specified format. Make sure the applications are relevant in the current market and industrial usage. Don't use words like "main uses"

"application1" or similar words

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Hyperhidrosis Treatment
Pharmaceuticals
Dermira
Development of unique antiperspirant drugs like Qbrexza which contains Glycopyrronium Tosylate as a key component.
Respiratory Disorders Treatment
Healthcare
Sosei Heptares
The strategic focus on designing inhaler-based treatments with Glycopyrronium Tosylate for respiratory conditions such as chronic obstructive pulmonary disease.
Peptic Ulcer Treatment
Medicine
Allergan
Inclusion of Glycopyrronium Tosylate in leading peptic ulcer treatment medicines such as Anaspaz, designed to reduce stomach acid.
Ophthalmology
Eye Care
Bausch Health
Development of advanced eye care solutions like liquid drops containing Glycopyrronium Tosylate to control production of tears in eyes.

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Glycopyrronium Tosylate market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Glycopyrronium Tosylate in Reducing Salivary Secretions, Bronchodilation Therapy and Hyperhidrosis Treatment

Reducing Salivary Secretions

Another frequent application of Glycopyrronium Tosylate is in managing excessive salivation, in particular with patients with neurodegenerative disorders like Parkinsons disease. It is mostly consumed orally in this application. It functions by hindering nerve impulses responsible for salivation, thereby aiding in controlling the symptoms experienced by patients.

Bronchodilation Therapy

Glycopyrronium Tosylate serves as an effective medication in bronchodilation therapy. In this regard, it is primarily used in aerosol form to be inhaled using a nebulizer. By causing bronchial muscle relaxation, it helps improve airflow to the lungs and is beneficial for patients suffering from COPD . Companies like Sandoz and Mylan lead the market in this regard, banking on their technical expertise and extensive geographical reach.

Hyperhidrosis Treatment

Glycopyrronium Tosylate is extensively used in the treatment of hyperhidrosis, a condition characterized by excessive sweating. The key of Glycopyrronium Tosylate used for this application is topical, often in the form of gels or sprays. It functions by blocking the sweat glands from responding to nervous stimuli thereby controlling sweating. Companies such as Dermira and GlaxoSmithKline hold considerable market share in this segment owing to their compelling product offerings and vast presence.

Glycopyrronium Tosylate vs. Substitutes:
Performance and Positioning Analysis

Glycopyrronium Tosylate effectively stands distinct from its alternatives due to its exceptional efficacy and broader therapeutic index. Its unique market positioning, driven by increasing demand in the dermatological sector, signals significant potential for growth

Glycopyrronium Tosylate
  • Oxybutynin Chloride /
  • Tolterodine Tartrate /
  • Darifenacin Hydrobromide
    Effective in managing symptoms of chronic obstructive pulmonary disorder (COPD), Useful in treating excessive sweating
    Potential side effects like dry mouth and urinary retention
    Higher versatility, broader spectrum of use
    Increased risk of side effects, potential for drug resistance

Glycopyrronium Tosylate vs. Substitutes:
Performance and Positioning Analysis

Glycopyrronium Tosylate

  • Effective in managing symptoms of chronic obstructive pulmonary disorder (COPD), Useful in treating excessive sweating
  • Potential side effects like dry mouth and urinary retention

Oxybutynin Chloride / Tolterodine Tartrate / Darifenacin Hydrobromide

  • Higher versatility, broader spectrum of use
  • Increased risk of side effects, potential for drug resistance

Glycopyrronium Tosylate effectively stands distinct from its alternatives due to its exceptional efficacy and broader therapeutic index. Its unique market positioning, driven by increasing demand in the dermatological sector, signals significant potential for growth

Loading...

Research Methodology

This market research methodology defines the Glycopyrronium Tosylate market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Glycopyrronium Tosylate across Hyperhidrosis Treatment, Bronchodilation Therapy, and Reducing Salivary Secretions Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Novartis, AstraZeneca, and Teva Pharmaceutical Industries by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, Chemical Synthesis, and Drug formulating. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Glycopyrronium Tosylate segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (Sigma-Aldrich, Fisher Scientific), Chemical Synthesis (GSK, Novartis), and Drug formulating. Our parallel substitute analysis examines Oxybutynin Chloride, Tolterodine Tartrate, and Darifenacin Hydrobromide, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Novartis, AstraZeneca, and Teva Pharmaceutical Industries, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Glycopyrronium Tosylate market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Glycopyrronium Tosylate Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 458 million
Revenue Forecast in 2034USD 1.53 billion
Growth RateCAGR of 14.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024400 million
Growth OpportunityUSD 1.1 billion
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024400 million USD
Market Size 2027598 million USD
Market Size 2029782 million USD
Market Size 2030894 million USD
Market Size 20341.53 billion USD
Market Size 20351.74 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredDosage Form, Application Areas, End-Use, Distribution Channel
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledNovartis, AstraZeneca, Teva Pharmaceutical Industries, Mylan, Sandoz, Sun Pharmaceutical Industries, GlaxoSmithKline, Perrigo Company, Jubilant Lifesciences, Cipla, Wockhardt and Lupin Pharmaceuticals
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Glycopyrronium Tosylate Market Size, Opportunities & Strategic Insights, by Dosage Form

4.1Pre-moistened Topical Wipe
4.2Cream
Chapter 5

Glycopyrronium Tosylate Market Size, Opportunities & Strategic Insights, by Application Areas

5.1Hyperhidrosis Treatment
5.2Bronchodilation Therapy
5.3Reducing Salivary Secretions
5.4Dermatologic Disorders
5.5Others
Chapter 6

Glycopyrronium Tosylate Market Size, Opportunities & Strategic Insights, by End-Use

6.1Pharmaceuticals
6.2Cosmetics
6.3Veterinary Medicine
6.4Others
Chapter 7

Glycopyrronium Tosylate Market Size, Opportunities & Strategic Insights, by Distribution Channel

7.1Hospital Pharmacies
7.2Retail Pharmacies
7.3Online Pharmacies
Chapter 8

Glycopyrronium Tosylate Market, by Region

8.1North America Glycopyrronium Tosylate Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Glycopyrronium Tosylate Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Glycopyrronium Tosylate Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Glycopyrronium Tosylate Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Glycopyrronium Tosylate Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Glycopyrronium Tosylate Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Novartis
9.2.2AstraZeneca
9.2.3Teva Pharmaceutical Industries
9.2.4Mylan
9.2.5Sandoz
9.2.6Sun Pharmaceutical Industries
9.2.7GlaxoSmithKline
9.2.8Perrigo Company
9.2.9Jubilant Lifesciences
9.2.10Cipla
9.2.11Wockhardt
9.2.12Lupin Pharmaceuticals